Inception IBD Inc., a Québec-based biotechnology company, and Inserm Transfer Initiative, have entered an exclusive, strategic collaboration with Celgene to discover and develop therapeutics for ulcerative colitis and Crohn’s disease.   Inception IBD will work to advance small molecule therapeutics from preclinical discovery to late preclinical development and is eligible to receive as much as $40 million during the course of the collaboration. The alliance allows Inception IBD to significantl...